Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | KLK1 | P06870 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272910 | 0.83 | PDE10A (0.53) | PDE10AKLKB1KLK1CXCR4GAA | |
| SCHEMBL29227340 | 0.80 | PDE10A (0.50) | PDE10AKLKB1KLK1CXCR4GAA | |
| SCHEMBL29907771 | 0.80 | PDE10A (0.50) | PDE10AKLKB1KLK1CXCR4GAA | |
| SCHEMBL6475308 | 0.80 | GAA (0.51) | PDE10ATRPV3KLKB1KLK1CXCR4 | |
| SCHEMBL29866072 | 0.80 | PDE10A (0.50) | PDE10ACXCR4GAAHTTTSHR | |
| SCHEMBL1844501 | 0.80 | PDE10A (0.50) | PDE10ACXCR4GAAHTTTSHR | |
| SCHEMBL1303138 | 0.80 | PDE10A (0.50) | PDE10AKLKB1KLK1CXCR4GAA | |
| SCHEMBL9944490 | 0.79 | PDE10A (0.50) | PDE10ACYP3A4KLKB1KLK1CXCR4 | |
| SCHEMBL6843345 | 0.78 | GAA (0.59) | PDE10ACXCR4GAAHTTTSHR | |
| SCHEMBL17503897 | 0.77 | KLKB1 (0.53) | PDE10ACYP3A4KLKB1KLK1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PDE10A 3241/4885CYP3A4 2583/4885TRPV3 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.